Furthermore, whilst rituximab does little to affect the overall T cell numbers in the PB pre- and post-therapy [30], one study found that rituximab selectively depleted TH17 cells in the synovium of RA patients [31], which similar to the MS studies, may be the result of their CD20 positivity. The gene discussed is MS4A1; the disease is rheumatoid arthritis.